Innospec Stock Price, News & Analysis (NASDAQ:IOSP)

Innospec trades on the NASDAQ under the ticker symbol "IOSP."

Innospec announced a Semi-Annual dividend on Tuesday, May 7th. Stockholders of record on Tuesday, May 21st will be paid a dividend of $0.50 per share on Thursday, May 30th. This represents a dividend yield of 1.18%. The ex-dividend date is Monday, May 20th. View Innospec's Dividend History.

Innospec Inc. (NASDAQ:IOSP) posted its quarterly earnings data on Tuesday, August, 6th. The specialty chemicals company reported $1.12 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.10 by $0.02. The specialty chemicals company earned $362.40 million during the quarter, compared to the consensus estimate of $371.20 million. Innospec had a return on equity of 15.11% and a net margin of 6.10%. Innospec's revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.80 earnings per share. View Innospec's Earnings History.

Innospec is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Innospec.

2 equities research analysts have issued twelve-month price objectives for Innospec's stock. Their forecasts range from $83.00 to $95.00. On average, they expect Innospec's stock price to reach $89.00 in the next twelve months. This suggests that the stock has a possible downside of 1.9%. View Analyst Price Targets for Innospec.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innospec in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innospec.

Media headlines about IOSP stock have been trending somewhat negative this week, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Innospec earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media headlines about the specialty chemicals company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Innospec.

Innospec saw a decline in short interest during the month of August. As of August 31st, there was short interest totalling 310,600 shares, a decline of 17.2% from the July 31st total of 375,100 shares. Based on an average trading volume of 117,300 shares, the short-interest ratio is presently 2.6 days. Approximately 1.3% of the company's stock are sold short. View Innospec's Current Options Chain.

Some companies that are related to Innospec include Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co (GRA), KURARAY CO LTD/ADR (KURRY), Univar (UNVR), Ingevity (NGVT), Balchem (BCPC), Olin (OLN), Chemours (CC), PQ Group (PQG), GCP Applied Technologies (GCP), Loop Industries (LOOP), Innophos (IPHS) and Hawkins (HWKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innospec investors own include Intellia Therapeutics (NTLA), NVIDIA (NVDA), Applied Materials (AMAT), Broadcom (AVGO), Lam Research (LRCX), Boeing (BA), Colgate-Palmolive (CL), XPO Logistics (XPO), Zayo Group (ZAYO) and Adobe (ADBE).

Innospec's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (16.93%), BlackRock Inc. (16.92%), Vanguard Group Inc. (10.52%), Wells Fargo & Company MN (4.99%), Price T Rowe Associates Inc. MD (2.49%) and Northern Trust Corp (2.27%). Company insiders that own Innospec stock include Brian Watt, Catherine Hessner, David Earl Williams, Hugh Aldous, Ian Cleminson, Ian Malcolm Mcrobbie, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View Institutional Ownership Trends for Innospec.

IOSP stock was sold by a variety of institutional investors in the last quarter, including Westwood Holdings Group Inc., First Wilshire Securities Management Inc., Eagle Asset Management Inc., SG Americas Securities LLC, James Investment Research Inc., Emerald Advisers LLC, Kirr Marbach & Co. LLC IN and Acadian Asset Management LLC. Company insiders that have sold Innospec company stock in the last year include Brian Watt, Catherine Hessner, Ian Cleminson, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View Insider Buying and Selling for Innospec.

IOSP stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, Wasatch Advisors Inc., Jacobs Levy Equity Management Inc., Northern Trust Corp, Wells Fargo & Company MN and Zacks Investment Management. View Insider Buying and Selling for Innospec.

Shares of IOSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IOSP stock can currently be purchased for approximately $90.77.

Innospec has a market capitalization of $2.22 billion and generates $1.48 billion in revenue each year. The specialty chemicals company earns $85 million in net income (profit) each year or $4.83 on an earnings per share basis. Innospec employs 2,000 workers across the globe.View Additional Information About Innospec.

The official website for Innospec is http://www.innospecinc.com/.

Innospec's mailing address is 8310 SOUTH VALLEY HIGHWAY SUITE 350, ENGLEWOOD CO, 80112. The specialty chemicals company can be reached via phone at 303-792-5554 or via email at [email protected]